What Can I Compare With The Pep Nation Lab Comparison Tool?

Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.

What Does The Evidence Tier Mean?

The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.

How Are "X vs Y" Comparison Pages Built?

Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.

Is Any Of This Medical Or Dosing Advice?

No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.

Compare Compounds

Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only

2/4

Diff ModeHide Identical

SurvodutideB86

TirzepatideA+98

Top Pick: TirzepatideTap to see full verdict & analysis

Survodutide

0/100

Grade B

Leads in evidence strength

Evidence

Safety

Science

Coverage

Handling

Depth

Tirzepatide

0/100

Grade A+

Leads in evidence strength

Evidence

Safety

Science

Coverage

Handling

Depth

Research Profile Radar - hover axes for details

Survodutide

Tirzepatide

Zoom100%

Attribute	Survodutide B	Tirzepatide A+
Research Summary	Survodutide is a dual-action weight loss powerhouse. It kills your appetite so you do not want to eat, while simultaneously turning up your body's heat to burn off stubborn fat directly from the liver.	Tirzepatide is a super-advanced weight loss signal. It acts like two different hormones combined into one, stopping your hunger completely while also making your body process sugars flawlessly.
Studied For	Obesity / overweightType 2 diabetesMASH / metabolic liver diseaseNon-alcoholic steatohepatitis (NASH)Liver fat reductionDual GLP-1 glucagon therapyHbA1c loweringBody weight reductionCardiovascular risk reductionInsulin resistanceMetabolic syndromeHepatic steatosisLipid metabolismweight lossliver fat reductionNASHNAFLDobesityenergy expenditure increase	Type 2 diabetes managementChronic weight management / obesityObstructive sleep apnea in obesity (FDA approved 2024)Non-alcoholic fatty liver disease (NAFLD/MASH)Cardiovascular risk reductionHbA1c loweringBody weight reduction superior to semaglutideInsulin resistanceMetabolic syndromePolycystic ovary syndromeKidney disease in diabetesHeart failure with obesityAppetite suppression dual pathwayLean mass preservationweight lossdiabetesfat lossappetite suppressionobesitymetabolic syndromeinsulin sensitivityA1C reduction
Research Areas	MetabolicWeight Management & Fat Loss	MetabolicWeight Management & Fat Loss
Best Stacked With	l-carnitineb12bac-water	l-carnitineb12lipo-cbac-water
Overview
Category	Weight Loss & Metabolism	Weight Loss & Metabolism
Compound Class	Synthetic dual agonist: GLP-1 receptor + glucagon receptor	Dual GIP/GLP-1 receptor co-agonist (twincretin); synthetic 39-residue peptide with C18 fatty diacid for albumin binding
Molecular Target	GLP-1R (satiety, insulin secretion) + GCGR (glucagon receptor: energy expenditure, hepatic lipid metabolism); dual incretin-glucagon signaling	GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression
Aliases / AKA	BI 456906BI-456906Survodutide peptideGLP-1 glucagon dual agonist BI 456906Boehringer dual agonistGCGR GLP-1R dual agonist	MounjaroZepboundLY3298176Tirzepatide peptideGIP GLP-1 dual agonistEli Lilly dual agonist
Parent Compound	Oxyntomodulin-based	Incretin dual agonist
Molecular Weight	4231.63 Da	4813.45 Da
Amino Acid Sequence	`GLP-1/glucagon dual agonist (acylated synthetic peptide)`	`39-aa acylated peptide (C20 diacid)`
CAS Number	2805997-46-8	2023788-19-2
Year Discovered	Not Listed	Not Listed
Pro-Angiogenic	No	No
GLP-1 Class
Purity	Not Listed	Not Listed
Identity
Evidence Tier
Risk Level
PubMed Citations	420 Good	2,193 Extensive
Clinical Trials	88 Active	174174 Active
Regulatory Status	Investigational (Boehringer Ingelheim / Zealand Pharma); not FDA-approved.	FDA-approved; compounded versions are not FDA-evaluated.
Evidence & Regulatory
Half-Life	~1 week	~1 week
Typical Frequency	Not Listed	Not Listed
Administration Route	Injection Only	Injection Only
Mechanism / PK	Not Listed	Not Listed
Reported Findings	Pooled trial data associate 4 to 11 months of treatment with roughly 7 to 9 percent weight reduction, plus Phase 2 liver-disease activity.	Strong human trials (SURPASS, SURMOUNT), superior to semaglutide on weight in a head-to-head; FDA-approved for diabetes, obesity, and sleep apnea.
Side Effects Noted	Predominantly gastrointestinal; glucagon agonism can raise heart rate.	Dose-dependent gastrointestinal effects; gallbladder and pancreatitis signals.
Warnings	Investigational with no approved indication or long-term safety data; GLP-1 class considerations under study. Research use only.	FDA boxed warning for thyroid C-cell tumors; contraindicated with personal or family medullary thyroid carcinoma or MEN 2. Approved product is distinct from compounded versions.
Pharmacology
Form	lyophilized	lyophilized (research) or pen/vial
Diluent	bacteriostatic or sterile water	bacteriostatic water
Storage Temp	frozen/refrigerated, dark	Refrigerate 2-8°C
Light Sensitive	Yes	Yes
Freeze / Thaw	avoid	avoid
Handling Notes	Note: catalog lists this as Survotutide (spelling).	Avoid freeze-thaw, heat, and shaking.
Reconstituted Shelf Life	28 Days Refrigerated	28 Days Refrigerated
Handling & Storage

Popular Research Comparisons

BPC-157 vs TB-500 / Thymosin Beta-4
The two most-studied research peptides for tissue repair and recovery.
Semaglutide vs Tirzepatide
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Tirzepatide vs Retatrutide
Dual versus triple incretin receptor agonists in weight-research models.
Semaglutide vs Retatrutide
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
CJC-1295 With DAC vs Ipamorelin
A GHRH analog versus a selective ghrelin-receptor secretagogue.
Ipamorelin vs Sermorelin
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Sermorelin vs Tesamorelin
Two GHRH analogs studied on the growth-hormone axis.
GHRP-2 vs GHRP-6
The two first-generation growth-hormone releasing peptides.
Cagrilintide vs Semaglutide
An amylin analog versus a GLP-1 agonist in metabolic research.
MOTS-c vs AOD9604
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
PT-141 vs Kisspeptin-10
Melanocortin versus kisspeptin pathways in reproductive research.
Epithalon vs NAD+
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
Hexarelin vs Ipamorelin
A potent versus a highly selective ghrelin-receptor secretagogue.
CJC-1295 With DAC vs Tesamorelin
Two GHRH analogs with contrasting half-life profiles.
IGF-1 LR3 vs Ipamorelin
A direct IGF-1 analog versus a growth-hormone secretagogue.
CJC-1295 With DAC vs CJC-1295 Without DAC
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Selank vs Semax
Two Russian-developed nootropic and anxiolytic research peptides.
SS-31 vs MOTS-c
Two mitochondrial-targeted peptides in cellular-energy research.
Thymosin Alpha-1 vs LL-37
Two immune-modulating research peptides with distinct mechanisms.
AOD9604 vs HGH Fragment 176-191
Two HGH-fragment analogs studied for fat-metabolism research.
Retatrutide vs Survodutide
Next-generation multi-receptor incretin agonists in metabolic research.
BPC-157 vs GHK-Cu
Two leading tissue-repair peptides with distinct healing mechanisms.
TB-500 / Thymosin Beta-4 vs GHK-Cu
A systemic repair peptide versus a copper peptide for tissue and skin research.
Tesamorelin vs Ipamorelin
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
Tirzepatide vs Cagrilintide
A dual incretin agonist versus an amylin analog in metabolic research.
Retatrutide vs Cagrilintide
A triple incretin agonist versus an amylin analog in weight research.
MOTS-c vs 5-Amino-1MQ
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ vs MOTS-c
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
GHK-Cu vs AHK-Cu
Two copper research peptides studied for skin and hair.
CJC-1295 With DAC vs Sermorelin
A long-acting versus a short-acting GHRH analog.
Ipamorelin vs GHRP-6
A selective versus a first-generation ghrelin-receptor secretagogue.
Semaglutide vs The Appetite Crusher Stack
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
BPC-157 vs KPV
Two peptides studied for gut and mucosal repair.
PT-141 vs Oxytocin
Melanocortin versus oxytocin pathways in intimacy and libido research.
Thymosin Alpha-1 vs Thymalin
Two thymic immune-modulating research peptides.
Selank vs DSIP
An anxiolytic nootropic versus a sleep-associated research peptide.
IGF-1 LR3 vs Follistatin
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
SS-31 vs NAD+
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
BPC-157 vs The Wolverine Stack
Single BPC-157 versus the combined BPC-157 and TB-500 blend in recovery research.
Ipamorelin vs The Fountain of Youth Stack
Ipamorelin alone versus the CJC-1295 and ipamorelin blend on the growth-hormone axis.
Semax vs Cerebrolysin
A synthetic ACTH-fragment nootropic versus a neurotrophic peptide preparation in cognitive research.
Melatonin vs DSIP
Two sleep-research compounds with distinct mechanisms.
GHK-Cu vs SNAP-8
A copper tripeptide versus an acetyl hexapeptide in cosmetic and skin research.
FOXO4-DRI vs Epithalon
A senolytic peptide versus a telomerase-pathway peptide in longevity research.
AICAR vs 5-Amino-1MQ
Two metabolic research compounds targeting the AMPK and NNMT pathways.
Tesamorelin vs HGH Fragment 176-191
A GHRH analog versus an HGH fragment in fat-metabolism research.
MOTS-c vs AICAR
Two AMPK-associated mitochondrial and metabolic research compounds.
ARA-290 vs BPC-157
Two peptides studied for tissue protection and repair.
VIP vs KPV
Two peptides studied for immune and inflammatory modulation.
Pinealon vs Epithalon
Two peptide bioregulators studied in longevity and neuro research.
Survodutide vs Tirzepatide
A glucagon/GLP-1 dual agonist versus a GIP/GLP-1 dual agonist in metabolic research.

Accessing Library

Compare Compounds

Compare Research Peptides Side By Side

Popular Research Comparisons

Compounds You Can Compare

Comparison Tool FAQ